Why BeiGene Stock Jumped Thursday
Shares of BeiGene (NASDAQ: BGNE) rose 14.3% by late Thursday afternoon and closed the day 12.48% higher. The Chinese biotech company recently signed a collaboration deal with Israel biotech company Enlivex Therapeutics to evaluate the safety and efficacy of cancer therapy Allocetra as a combination therapy with tislelizumab, which BeiGene will supply, to treat advanced-stage solid tumors. BeiGene's shares are up more than 8% so far this year.